Provided by Tiger Fintech (Singapore) Pte. Ltd.

MoonLake Immunotherapeutics

46.88
-1.9500-3.99%
Post-market: 46.880.00000.00%18:52 EDT
Volume:881.42K
Turnover:42.17M
Market Cap:2.98B
PE:-20.35
High:49.81
Open:49.25
Low:46.73
Close:48.83
Loading ...

BTIG Adjusts MoonLake Immunotherapeutics' Price Target to $81 From $71, Keeps Buy Rating

MT Newswires Live
·
09 Jan

MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG

TIPRANKS
·
09 Jan

Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and Accolade (ACCD)

TIPRANKS
·
09 Jan

MoonLake Immunotherapeutics : Btig Raises Target Price to $81 From $71

THOMSON REUTERS
·
09 Jan

MoonLake's Three New Trials Will Expand Sonelokimab's Potential, Wedbush Says

MT Newswires Live
·
09 Jan

MoonLake Immunotherapeutics Starts Three New Clinical Trials Evaluating Sonelokimab in Inflammatory Diseases

MT Newswires Live
·
09 Jan

BRIEF-Moonlake Initiates Three New Clinical Trials And Expands Portfolio Of Indications For The Nanobody Sonelokimab

Reuters
·
08 Jan

MoonLake Immunotherapeutics - Phase 2 and 3 Data Read-Outs Expected in 2025 and 2026

THOMSON REUTERS
·
08 Jan

MoonLake Immunotherapeutics - Primary Endpoint of S-Olaris Trial Is Change in 18F-Naf Uptake

THOMSON REUTERS
·
08 Jan

MoonLake Immunotherapeutics - Running Seven Trials in 2025

THOMSON REUTERS
·
08 Jan

MoonLake Initiates Three New Clinical Trials and Further Expands the Portfolio of Indications for the Nanobody® Sonelokimab

THOMSON REUTERS
·
08 Jan

MoonLake Immunotherapeutics Announces Board Changes and Incentives

TIPRANKS
·
19 Dec 2024

Stifel Nicolaus Sticks to Its Buy Rating for MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
17 Dec 2024

Oppenheimer Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
11 Dec 2024